Long non-coding RNA expression profiles in gallbladder carcinoma identified using microarray analysis

JIWEN WANG1,2*, HAN LIU1*, XIAOKUN SHEN3, YUEQI WANG1, DEXIANG ZHANG4,
SHENG SHEN1, TAO SUO1, HONGTAO PAN1, YUE MING5, KAN DING2 and HOUBAO LIU1

1Department of General Surgery, Zhongshan Hospital, General Surgery Institute, Fudan University, Shanghai 200032; 2Glycobiology and Glycochemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203; 3Department of Surgical Oncology, Taizhou Hospital, Wenzhou Medical University, Taizhou, Zhejiang 317000; 4Department of General Surgery, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240; 5PET-CT Center, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, P.R. China

Received September 23, 2015; Accepted December 9, 2016

DOI: 10.3892/ol.2017.5893

Abstract. Gallbladder carcinoma (GBC) is the most common biliary tract cancer and exhibits poor patient prognosis. Previous studies have identified that long non-coding RNAs (lncRNAs) serve important regulatory roles in cancer biology. Alterations in lncRNAs are associated with several types of cancer. However, the contribution of lncRNAs to GBC remains unclear. To investigate the lncRNAs that are potentially involved in GBC, lncRNA profiles were identified in three pairs of human GBC and corresponding peri-carcinomatous tissue samples using microarray analysis. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to validate the microarray data. In order to elucidate potential functions, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes analysis, and network analysis were used to determine relevant signaling pathways. Abundant RNA probes were used, and 1,758 lncRNAs and 1,254 mRNAs were detected to be differentially expressed by the microarray. Compared with para-carcinoma tissue, numerous lncRNAs were markedly upregulated or downregulated in GBC. The results demonstrated that the lncRNAs that were downregulated in GBC were more numerous compared with the lncRNAs that were upregulated. Among them, RP11-152P17.2-006 was the most upregulated, whereas CTA-941F9.9 was the most downregulated. The RT-qPCR results were consistent with the microarray data. Pathway analysis indicated that five pathways corresponded to the differentially expressed transcripts. It was demonstrated that lncRNA expression in GBC was markedly altered, and a series of novel lncRNAs associated with GBC were identified. The results of the present study suggest that the functions of lncRNAs are important in GBC development and progression.

Introduction

Gallbladder carcinoma (GBC) is the most common biliary tract cancer and a common type of cancer of the gastrointestinal tract (1). The incidence and distribution of GBC differs by region (2,3); for example, the prevalence of GBC in South and East Asia is increased compared with that in Europe and the Americas (4). Surgical resection is the only treatment for GBC; however, the majority of patients are not candidates for curative resection when they are diagnosed, and patients with advanced stages of the disease are likely to exhibit recurrences following surgery (5). Although there have been advances in chemotherapy, the prognosis of GBC remains poor (6). The mean survival ranges between 5.2 and 24.4 months (7-10). The majority of patients with GBC succumb to metastasis and recurrence following surgery. Although previous studies have reported that accumulated genomic damage promotes GBC progression (11,12), the underlying molecular mechanisms of GBC progression remain unclear.

Previous studies have identified non-coding RNAs (ncRNAs) as principal components of the human transcriptome (13,14). According to their length, ncRNAs may be...
divided into two types: Long ncRNAs (lncRNAs) and small regulatory RNAs. lncRNAs have lengths of between 200 bp and 100 kb (15). Increasing evidence in previous years has determined that ncRNAs serve important regulatory roles in cellular physiological processes and diseases (16), including Huntington's disease (17), Alzheimer's disease (18), and glioma, lung, colorectal, breast cancer and hepatocellular cancer (19-22). Accordingly, lncRNA dysregulation, including metastasis-associated lung adenocarcinoma transcript 1, colon cancer-associated transcript 1, homeobox transcript antisense RNA (HOTAIR) and low expression in tumor, is also associated with GBC (23-26). Although numerous lncRNAs have been discovered over the previous decade, the biological functions of lncRNAs in GBC and their underlying molecular mechanisms remain unclear. Using microarray analysis, 654 lncRNAs and 1,057 mRNAs that were markedly aberrantly expressed in GBC and paired peri-carcinomatous tissue samples were identified. The results were validated using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and were consistent with the data analysis of the profiles. Co-expression networks of lncRNAs and mRNAs, as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, were used to determine the biological processes for lncRNAs. The results of the present study demonstrated that aberrantly expressed lncRNAs may serve a role in the occurrence and development of GBC.

Materials and methods

Ethics statement. All aspects of the present study were approved by the Zhongshan Hospital Research Ethics Committee (Zhongshan Hospital, Fudan University, Shanghai, China). All patients provided written informed consent for the use of their surgical specimens in the present study in accordance with the Committee's regulations. The clinical characteristics of the patients with GBC are presented in Table I. Tissue specimens were selected randomly from Zhongshan Hospital, Fudan University (Shanghai, China) between April and September 2014.

Extraction of total RNA and RT-qPCR. Paired tissues of GBC and peri-carcinomatous tissues from each patient were quick-frozen in liquid nitrogen immediately following resection and stored at -80°C. Total RNA was isolated using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. A BioPhotometer® plus 6132 instrument (Eppendorf, Hamburg, Germany) was used to measure RNA concentrations. Total RNA (1 µg) was reverse transcribed into complementary RNA (cRNA) containing Ribosomal RNA was removed from total RNA using an mRNA-ONLY™ Eukaryotic mRNA Isolation kit (Epicentre; Madison, WI, USA), according to the manufacturer's protocol, and discarded. Each mRNA sample was transcribed into complementary RNA (cRNA) containing cyanine-3-cytidine 5'-triphosphate fluorescent labels (Agilent Technologies, Inc., Santa Clara, CA, USA). Klenow enzyme labeling strategy was adopted following reverse transcription using CbcScript II reverse transcriptase. Labeled cDNA was produced by Eberwine's linear RNA amplification method and subsequent enzymatic reaction. This procedure has been previously described, and the procedure has been improved by using CapitalBio cRNA Amplification and Labeling kit

| Table I. Clinical characteristics of 23 gallbladder carcinoma cases. |
|-----------------|--------|--------|--------|--------|--------|
| Patient no. | Age, years | Gender | T | N | M |
| P1 | 69 | F | 3 | 0 | 0 | IIIA |
| P2 | 51 | M | 2 | 0 | 0 | II |
| P3 | 62 | M | 3 | 1 | 0 | IIIB |
| P3 | 50 | F | 3 | 0 | 0 | IIIA |
| P4 | 40 | M | 1 | 0 | 0 | I |
| P5 | 50 | F | 3 | 0 | 0 | IIIA |
| P6 | 41 | F | 1b | 0 | 0 | I |
| P7 | 50 | F | 3 | 0 | 0 | IIIA |
| P8 | 71 | F | 4 | 1 | 0 | IVA |
| P9 | 60 | F | 4 | 2 | 1 | IVB |
| P10 | 51 | F | 1b | 0 | 0 | I |
| P11 | 57 | F | 1b | 0 | 0 | I |
| P12 | 65 | F | 3 | 0 | 0 | IIIA |
| P13 | 66 | M | 3 | 1 | 0 | IIIB |
| P14 | 57 | F | 2 | 2 | 0 | IVB |
| P15 | 78 | F | 1b | 0 | 0 | I |
| P16 | 68 | F | 2 | 0 | 0 | II |
| P17 | 41 | M | 3 | 1 | 0 | IIIB |
| P18 | 49 | M | 3 | 0 | 0 | IIIA |
| P19 | 76 | M | 3 | 1 | 0 | IIIB |
| P20 | 67 | F | 3 | 0 | 0 | IIIA |
| P21 | 62 | F | 4 | 2 | 1 | IVB |
| P22 | 66 | M | 3 | 0 | 0 | IIIA |
| P23 | 75 | M | 3 | 0 | 0 | IIIA |

T, tumor; N, node; M, metastasis; P, patient; F, female; M, male.

lncRNA and mRNA microarray expression profiling. Microarray hybridization was carried out by the CapitalBio Corporation (Shanghai, China) on behalf of the present study. Ribosomal RNA was removed from total RNA using an mRNA-ONLY™ Eukaryotic mRNA Isolation kit (Epicentre; Illumina, Madison, WI, USA), according to the manufacturer's protocol, and discarded. Each mRNA sample was transcribed into complementary RNA (cRNA) containing reference (the β-actin primers were purchased from Sangon Biotech Co., Ltd., Shanghai, China). The amplification conditions were as follows: Reverse transcription reaction at 42°C for 30 min per cycle. The PCR cycling conditions were as follows: Enzyme activation at 95°C for 10 sec per 40 cycles, and annealing and extension at 60°C for 32 sec.
Co-expression network construction. An IncRNA-mRNA co-expression network was constructed to determine their association, and the algorithm was as follows: i) The data were preprocessed for median gene expression values of all transcripts from the same coding gene, without special treatment for IncRNAs; ii) data for aberrantly expressed IncRNAs and mRNAs were removed following screening; iii) Pearson’s correlation coefficient (PCC) was calculated and the R value was used to calculate the PCC between IncRNAs and mRNAs; and iv) the data were screened and data for which the PCC was >0.99 were selected. The gene co-expression network was constructed using Cytoscape software version 3.1.1 (U.S. National Institute of General Medical Sciences, Washington, DC, USA).

In the network, yellow nodes represented the IncRNAs and green nodes represented the mRNAs. Circular nodes represented IncRNAs and diamond nodes represented the mRNAs. Continuous lines indicated a positive association and dashed lines indicated a negative association.

Cell culture. The human GBC cell line SGC-996 was provided by the Tumor Cytology Research Unit (Medical College, Tongji University, Shanghai, China). Human GBC cell line GBC-SD was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 mg/ml streptomycin and 100 units/ml penicillin. Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2.

siRNA transfection. RP5-899B16.2-specific siRNAs and non-silencing negative control siRNA were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China; product ID siP01001). The target sequences of RP5-899B16.2 were 5’-GGAUAGAUACAUUGACACUdTdT-3’ (siRNA-1) and 5’-GGAUAGAUACGUUCCAUCdTdT-3’ (siRNA-2). SGC-996 and GBC-SD cells were transfected with Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol.

Cell viability. Transfected and non-transfected SGC-996 cells and GBC-SD cells were seeded into 96-well plates at a concentration of 3x10^3 cells/well and 2.5x10^4 cells/well, respectively. Between days 1 and 5, 10 μl MTT solution with solvent PBS was added to each well of one plate, followed by incubation at 37°C for 4 h. The absorbance at 490 nm was measured using a microplate reader. The assay was performed in triplicate.

Statistical analysis. All statistical analyses were performed using SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA). For comparison, a two-tailed Student’s t-test was performed, when appropriate. Data in Fig. 2 were presented as log2-transformed median fold-changes in expression ± standard error, and results in Fig. 5 were presented as the mean ± standard error of the mean. All histograms were constructed using Prism for Windows (version 5.0; GraphPad...
Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**lncRNA and mRNA expression profiles in GBC.** To analyze the expression profiles of lncRNAs between tumor tissue and PCT (para-carcinoma tissue), fold-changes (tumor tissue vs. PCT), P-values and FDRs were used to assess the normalized expression of genes. According to the microarray data, <17,032 lncRNAs and <22,848 mRNAs expressed in the three pairs of GBC and PCT were detected, which included 654 lncRNAs (229 upregulated and 425 downregulated) and 1,057 mRNAs (394 upregulated and 663 downregulated) with markedly different expression. In addition, 112 lncRNAs and 184 mRNAs were identified as consistently upregulated in all three GBC groups, whereas 283 lncRNAs and 427 mRNAs were consistently downregulated. The 30 most marked differentially expressed lncRNAs and mRNAs identified using microarray analysis are presented in Tables III and IV. The hierarchical clustering analysis dendrograms indicated that the samples exhibited associations among the lncRNA and mRNA expression patterns (Fig. 1A and B). Among the aberrantly expressed lncRNA transcripts, RP11‑152P17.2‑006 (log₂ fold-change tumor/wild-type=10.57) was the most markedly upregulated, whereas the expression of CTA‑941F9.9 (log₂ fold-change tumor/wild-type=‑15.00) was the most markedly downregulated. Subsequently, the results were compared with the microarray data deposited in the GEO, which demonstrated that 1,212 lncRNAs and 1,213 mRNAs were aberrantly expressed between five pairs of GBC and adjacent non-tumor samples (fold-change ≥1.25, P<0.05 and FDR<0.05). Three pairs of analogous samples were further analyzed, and 654 lncRNAs and 1,057 mRNAs aberrantly expressed in three

| Probe name | lncRNA ID | Gene symbol | P-value | FC | Regulation | Chromosome |
|------------|-----------|-------------|---------|----|------------|------------|
| p11051 | ENST00000422971.1 | CTA-941F9.9 | 0.017 | 15.00 | Down | 22(-): 46000311-46001501 |
| p7473 | ENST00000591222.1 | NA | 0.014 | 13.99 | Down | 17(+): 66186024-66188943 |
| p3312 | ENST00000551672.1 | NA | 0.021 | 13.56 | Down | 12(-): 80849274-80852604 |
| p13773 | ENST00000514158.1 | CTC-454M9.1 | 0.009 | 13.45 | Down | 5(+): 88185276-88237187 |
| p14911 | ENST00000449672.1 | AOAH-IT1 | 0.016 | 12.84 | Down | 7(-): 36637439-36639726 |
| p21662 | TCONS_00029197 | NA | 0.025 | 12.24 | Down | 21(+): 17979036-17997674 |
| p20932 | TCONS_00004444 | NA | 0.013 | 11.75 | Down | 2(-): 13032422-13035182 |
| p35139_v4 | ENST00000515376.1 | NA | 0.023 | 11.23 | Down | 4(+)174451610-174512475 |
| p35137_v4 | ENST00000512246.1 | NA | 0.026 | 11.14 | Down | 4(+)174451608-174462981 |
| p2150 | ENST00000436715.1 | H19 | 0.019 | 11.02 | Down | 11(-): 2016668-2017801 |
| p1587 | ENST00000454837.1 | ANTXRLP1 | 0.033 | 10.94 | Down | 10(−): 47620144-47640809 |
| p15983 | ENST00000520594.1 | NA | 0.039 | 10.57 | Up | 8(-): 106797231-107072695 |
| p16513 | ENST00000594708.1 | NA | 0.027 | 10.11 | Down | 9(-): 72080912-72873782 |
| p36138_v4 | TCONS_00010091 | NA | 0.025 | 9.44 | Down | 5(+)130589969-130593098 |
| p43626_v4 | XR_430247.1 | NA | 0.040 | 9.30 | Down | 19(+): 42060081-42061684 |
| p22857 | TCONS_00009823 | NA | 0.042 | 9.29 | Down | 5(-): 178365677-178368084 |
| p43270_v4 | XR_429785.1 | NA | 0.000 | 9.12 | Down | 16(+): 85196766-85199924 |
| p15702 | ENST00000523786.1 | NA | 0.002 | 8.87 | Down | 8(-): 57432776-57472056 |
| p15932 | ENST00000517869.1 | NA | 0.033 | 8.87 | Down | 8(-): 12693466-126993394 |
| p7444 | ENST00000580515.1 | BZRAP1-AS1 | 0.026 | 8.87 | Down | 17(+): 56406298-56429790 |
| p35142_v4 | ENST00000515345.1 | NA | 0.029 | 8.51 | Down | 4(+): 174451624-174458566 |
| p33555 | ENST00000460744.1 | NA | 0.022 | 8.06 | Down | 3(+): 111011565-111261149 |
| RNA33675|snoRNA _scaRNA_271_77 | RNA33675|snoRNA _scaRNA_271_77 | NA | 0.012 | 7.72 | Down | NA |
| p38655_v4 | ENST00000458974.1 | NA | 0.024 | 7.63 | Down | 14(+): 101364256-101364333 |
| p12993 | ENST00000509866.1 | NA | 0.036 | 7.62 | Down | 4(+): 174451612-174458842 |
| p13228 | ENST00000503568.1 | NA | 0.004 | 7.61 | Down | 5(-): 74343543-74348468 |
| p34010_v4 | ENST00000415582.1 | NA | 0.048 | 7.55 | Up | 1(-): 20196922-201970411 |
| RNA143553|tRNA _470_66 | RNA143553|tRNA _470_66 | NA | 0.018 | 7.45 | Down | NA |
| p4096 | ENST00000436329.1 | GPC6-AS1 | 0.020 | 7.44 | Down | 13(-): 94806446-94840245 |
| p40958_v4 | XR_427898.1 | NA | 0.028 | 7.43 | Down | 6(-): 25015198-25036372 |

**Table III. Microarray analysis of the 30 most aberrantly regulated lncRNAs in three pairs of gallbladder carcinoma tissues.**

IncRNA, long non-coding RNA; ID, identification no.; FC, fold-change; NA, not annotated.
Figure 1. Differences in the lncRNA and mRNA expression profiles between gallbladder carcinoma and non-tumorous tissues. (A) Results from hierarchical clustering demonstrate distinguishable (A) lncRNA and (B) mRNA expression profiling among samples. Red indicates increased relative expression and green indicates decreased relative expression. lncRNA, long non-coding RNA. T, tumor; N, wild-type.

Table IV. Microarray analysis of the 30 most aberrantly regulated mRNAs in three pairs of gallbladder carcinoma tissues.

| Probe name | Ensembl ID | Gene symbol | P-value | FC | Regulation | Chromosome |
|------------|------------|-------------|---------|----|------------|------------|
| A_23_P390700 | ENST00000550305 | CNTN1 | 0.037 | 21.52 | Down | 12: 41414156-41414215 |
| A_23_P134347 | ENST00000542995 | CPVL | 0.003 | 18.15 | Down | 7: 29105730-29105671 |
| A_33_P3265749 | ENST00000370934 | PTGER3 | 0.020 | 14.64 | Down | 1: 71478048-71477989 |
| A_23_P168993 | ENST00000345060 | ADRB3 | 0.049 | 13.94 | Down | 8: 37821117-37821058 |
| A_23_P150457 | ENST00000438354 | LYVE1 | 0.028 | 12.52 | Down | 11: 10580104-10580045 |
| A_24_P326935 | ENST00000424910 | KLK6 | 0.006 | 12.00 | Up | 19: 51466784-51466725 |
| A_33_P397865 | ENST00000291901 | TNN1 | 0.019 | 11.51 | Up | 19: 55644255-55644196 |
| A_33_P3290239 | NA | DUOXA1 | 0.017 | 11.51 | Up | 15: 45411363-45411304 |
| A_33_P3275801 | ENST00000373960 | DES | 0.031 | 11.51 | Down | 2: 220291400-220291459 |
| A_24_P261760 | ENST00000356986 | KLRG1 | 0.007 | 11.49 | Down | 12: 9147774-9147833 |
| A_33_P3254844 | ENST00000401731 | CEACAM7 | 0.005 | 11.48 | Up | 19: 42178513-42178454 |
| A_33_P3256997 | ENST00000398984 | NA | 0.029 | 11.05 | Down | 11: 59980755-59980696 |
| A_33_P3265739 | ENST00000306666 | PTGER3 | 0.021 | 10.98 | Down | 1: 71436629-71436570 |
| A_33_P3248405 | ENST00000356164 | NRK | 0.038 | 10.96 | Down | X: 105139249-105139308 |
| A_23_P145718 | ENST00000483864 | AOAH | 0.017 | 10.92 | Down | 7: 36570069-36561708 |
| A_33_P3294533 | ENST00000321728 | PRKCB | 0.040 | 10.62 | Down | 16: 24231495-24231554 |
| A_23_P339588 | ENST00000338313 | TAGAP | 0.011 | 10.37 | Down | 6: 159460015-159459956 |
| A_24_P40626 | ENST00000318160 | GREM2 | 0.013 | 10.08 | Down | 1: 240654036-240653977 |
| A_21_P0010449 | ENST00000422971 | XLOC_014399 | 0.012 | 10.05 | Down | 22: 46000392-4600333 |
| A_33_P3406196 | ENST00000344825 | KLRD1 | 0.036 | 9.97 | Down | 12: 10462019-10462078 |
| A_24_P156490 | ENST00000286627 | KCNA1 | 0.006 | 9.84 | Down | 10: 7864826-7864867 |
| A_33_P3225760 | ENST00000419293 | PCDH18 | 0.014 | 9.29 | Down | 4: 138453085-138453026 |
| A_33_P3220015 | ENST00000390341 | NA | 0.028 | 9.25 | Down | 7: 38339480-38339421 |
| A_23_P64898 | ENST00000538029 | KLRG1 | 0.047 | 9.24 | Down | 12: 9162594-9162653 |
| A_21_P0055574 | NA | XLOC_006224 | 0.028 | 9.12 | Down | 7: 123284900-123284959 |
| A_33_P3240512 | ENST00000377474 | KCTD12 | 0.043 | 8.94 | Down | 13: 77454410-77454351 |
| A_33_P3249872 | ENST00000262722 | FBLN1 | 0.031 | 8.54 | Down | 22: 45959173-45959232 |
| A_23_P145606 | ENST00000320658 | CHRM2 | 0.041 | 8.51 | Down | 7: 136700790-136700849 |
| A_33_P3257027 | ENST00000377614 | FGF7 | 0.025 | 8.51 | Down | 15: 49776810-49776869 |
| A_23_P342641 | ENST00000536707 | SLC44A5 | 0.021 | 8.42 | Up | 1: 75679412-75677201 |

ID, identification no.; FC, fold-change; NA, not annotated.
GBC tissues compared with the adjacent non-tumor samples were identified (fold-change ≥2.0, P<0.05 and FDR<0.05), which used a different fold-change threshold compared with previous results. If the fold-change was defined to be ≥1.5, the...
aberrant expression gene numbers were 1,565 lncRNAs and 2,321 mRNAs.

Validation of the microarray data using RT-qPCR. To validate the microarray analysis results, four upregulated/downregulated lncRNAs were randomly selected for validation using RT-qPCR. The results demonstrated that lncRNAs RP11-304L19.1 and colorectal neoplasia differentially expressed (CRNDE) were upregulated and CTA-941F9.9 and RP5-899B16.2 were downregulated in the tumor samples compared with PCT samples (Fig. 2). These RT-qPCR results were consistent with the microarray data.

GO and KEGG pathway analyses. To investigate potential gene and gene product enrichment in biological processes, cellular components and molecular functions, GO analysis was performed with the differentially expressed mRNAs. An FDR $\leq$0.05 (Bonferroni correction) was used to determine significant changes in the differentially expressed gene list and the GO annotation list. The results suggested that a number of functional signaling pathways were enriched, including those involved in the regulation of cell activation, external side of the plasma membrane, membrane rafts and regulation of immune system processes. In addition, the cell surfaces exhibited the most increased enrichment of GO terms within GBC (Fig. 3A). Pathway analyses indicated that five pathways corresponded to differentially expressed transcripts and were the human immunodeficiency virus-induced T cell apoptosis, T cytotoxic cell-surface molecules, T helper cell-surface molecules, primary immunodeficiency and the T cell receptor signaling pathways (Fig. 3B).

Construction of a co-expression network. To explore the association between lncRNAs differentially expressed in GBC and targeted mRNAs, a co-expression network was constructed. Using PCC $\geq$0.99 and $P<0.0001$, 5,679 pairs of co-expressed lncRNAs and mRNAs composed of 922 mRNAs (87.2% of all differentially expressed mRNAs) and 602 lncRNAs (92.0% of all differentially expressed lncRNAs) were identified, and 3,366 pairs demonstrated a positive association (Fig. 4). The results suggested that the lncRNA-mRNA pairs exhibiting the most marked positive correlation coefficient included XR_429508.1 and CD3γ, ENST00000451584.1 and transcription factor activator protein 2Aα exhibited the most marked negative correlation coefficient. This co-expression network indicated that 1 lncRNA may target $\leq$29 coding genes and that one coding gene may associate with $\leq$3 lncRNAs. For example, this network indicated that
Previous studies have indicated that lncRNAs serve important roles in regulating gene expression and are associated with cancer development (29,30), including HOTAIR in breast cancer (22), digestive system cancer (31) and urothelial cancer (32). The maternally expressed gene 3 was downregulated in several cancers and was demonstrated to inhibit tumor growth (33,34). CRNDE was upregulated in colorectal adenoma, adenocarcinoma and glioma (35,36). The majority of the aforementioned lncRNAs were also identified in the present study. However, studies on the association of lncRNA expression with GBC are limited (23-26). Therefore, it is important to understand the association between lncRNA expression and GBC to identify its pathogenesis. These results suggested that lncRNAs are potential targets for novel therapies.

In the present study, lncRNA and mRNA expression profiles in GBC were investigated using microarray chips. The results demonstrated that >100 lncRNA expression levels were changed compared with matched adjacent non-cancerous tissues. Currently, to the best of our knowledge, there are no studies on lncRNA expression profiles in GBC. The discrepancy between the data of the present study and GEO data may be due to differences in tumor tissues. Furthermore, the platform that was used was the Human lncRNA array V4.0 (4x180K), whereas the platform for the GEO data was the Affymetrix Human Gene 2.0 ST Array. The difference between the two platforms in array content, gene coverage availability, specific exon or splice junction probes, labeling systems and systematic lncRNA classification may lead to the difference in results. Therefore, novel lncRNAs were identified outside the scope of the GEO data. This avoided the elimination of lncRNAs that serve important roles in GBC.

In the previous decade, studies have suggested that a number of lncRNAs contribute to important functions, including the regulation of gene expression, serve an important role in cell development and metabolism, and are aberrant in a variety of diseases (13,37). To elucidate the underlying molecular mechanisms of lncRNA function, a co-expression network was further constructed by combining aberrantly expressed lncRNAs and mRNAs. Multiple lncRNAs were demonstrated to be markedly associated with mRNAs. CRNDE is an intergenic lncRNA located on chromosome 16, which is also overexpressed in colorectal carcinomas, gliomas and leukemias (35,38). CDCA7L is a target gene for cellular Myc proto-oncogene protein (c-Myc) that is involved in cell proliferative and apoptotic signaling pathways (39). However, SLC44A5 codes for a choline transporter-like protein that is associated with cell proliferation. Therefore, it was hypothesized that CRNDE may be a direct or indirect target gene of CDCA7L and SLC44A5. This lncRNA and mRNA co-expression network provides a strong foundation for predicting the function of lncRNAs. The malfunction of regulating this co-expression network may be an important step for the development and progression of GBC. The underlying molecular mechanisms of GBC progression remain unclear. Furthermore, GO analysis and pathway analysis were used to elucidate the biological functions of lncRNA in the occurrence and development of GBC. More research is required to elucidate the functions of lncRNAs.

In conclusion, the expression profiles of lncRNAs and mRNAs in GBC with microarray analyses were determined, and 654 lncRNAs and 1,057 mRNAs were identified; the majority of which were novel identifications in GBC. Additionally, an lncRNA-mRNA co-expression network

Figure 5. RP5-899B16.2 silencing affects the viability of gallbladder carcinoma cell lines. Expression of RP5-899B16.2 in (A) GBC-SD and (B) SGC-996 cell lines transfected with control siRNA or two siRNAs targeting RP5-899B16.2 (siRNA-1 and siRNA-2). 18S was used as the internal control. MTT assay of (C) GBC-SD and (D) SGC-996 cells transfected with NC, siRNA-1 and siRNA-2. Relative cell viability with respect to NC-treated cells (set as 1) of the (E) GBC-SD and (F) SGC-996 cell lines 96 h following siRNA transfection. siRNA-1: siRP5-899B16.2-1; siRNA-2: siRP5-899B16.2-2; *P<0.05; **P<0.001. siRNA, small interfering RNA; NC, negative control; OD, optical density.

CRNDE was associated with cell division cycle-associated 7-like (CDCA7L) and solute carrier 44A5 (SLC44A5).

Silencing of RP5-899B16.2 increased GBC cell viability. To further confirm the functional relevance of lncRNA expression, SGC-996 and GBC-SD cell lines were transfected with RP5-899B16.2-specific siRNAs and non-silencing negative control siRNA. The RT-qPCR results indicated that RP5-899B16.2 expression was markedly downregulated at the mRNA level in the two transfected cells compared with the control (Fig. 5A and B).

The frequent dysregulation of RP5-899B16.2 in GBC tissues and cell lines suggested that this gene may serve an important role in GBC. To investigate the effects of STMM1 deficiency, an MTT assay was performed and cell viability curves were constructed. It was demonstrated that the viability of the GBC cell lines increased markedly following the silencing of RP5-899B16.2 (Fig. 5C-F).

Discussion

The carcinogenesis of GBC is a complex process (1). Despite advances in research in recent decades, its pathogenesis remains unclear, and further studies are required. The association between lncRNAs and tumors has been frequently investigated. Previous studies have indicated that lncRNAs serve important roles in regulating gene expression and are associated with cancer
Expression Omnibus, no. GSE74048. The present study was supported by the National Natural Science Foundation of China (grant no. 81272728).

Acknowledgements

The Microarray data are publicly accessible via the Gene Expression Omnibus, no. GSE74048. The present study was supported by the National Natural Science Foundation of China (grant no. 81272728).

References

1. Zhu AX, Hong TS, Hezel AF and Kooby DA: Current management of gallbladder carcinoma. Oncologist 15: 168-181, 2010.
2. Miller G and Jarnagin WR: Gallbladder carcinoma. Eur J Surg Oncol 34: 306-312, 2008.
3. Randi G, Franceschi S and La Vecchia C: Gallbladder cancer worldwide: epidemiological, clinical, treatment and risk factors. Int J Cancer 118: 1591-1602, 2006.
4. Misra S, Chaturvedi A, Misra NC and Sharma ID: Carcinoma of the gallbladder. Lancet Oncol 4: 167-176, 2003.
5. Yamaguchi K, Chijiwa K, Saiki S, Nakamura K, Takashima M, Kawakami K and Tanaka M: Retrospective analysis of 70 operations for gallbladder carcinoma. Br J Surg 84: 200-204, 1997.
6. Grobmyer SR, Lieberman MD and Daly JM: Gallbladder cancer in the twentieth century: Single institution's experience. World J Surg 28: 47-49, 2004.
7. Wu XS, Shi LB, Li ML, Ding Q, Weng H, Wu WG, Cao Y, Bao RF, Shu YJ, Ding QC, et al: Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol 21: 449-457, 2014.
8. Bartlett DL, Fong Y, Fortner JG, Brennan MF and Blumgart LH: Long-term results after resection for gallbladder cancer: Implications for staging and management. Ann Surg 224: 639-646, 1996.
9. Butte JM, Matsuo K, Gönen M, D’Angelica MI, Waugh E, Allen PJ, Fong Y, DeMatteo RP, Blumgart L, Endo I, et al: Gallbladder cancer: Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212: 50-61, 2011.
10. Czupka K, Partecke LI, Mirow L, Langenbecks Arch Surg 379: 899-907, 2012.
11. Ooi A, Suzuki S, Nakazawa K, et al: European guidelines for gallbladder carcinoma: Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212: 50-61, 2011.
12. Czupka K, Partecke LI, Mirow L, Heidecke CD, Emde C, J Am Coll Surg 212: 49-58, 2011.
13. Czupka K, Partecke LI, Mirow L, et al: European guidelines for gallbladder carcinoma: Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212: 50-61, 2011.
14. Butte JM, Matsuo K, Gönen M, D’Angelica MI, Waugh E, Allen PJ, Fong Y, DeMatteo RP, Blumgart L, Endo I, et al: Gallbladder cancer: Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212: 50-61, 2011.
15. Czupka K, Partecke LI, Mirow L, Langenbecks Arch Surg 379: 899-907, 2012.
16. Ooi A, Suzuki S, Nakazawa K, et al: European guidelines for gallbladder carcinoma: Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212: 50-61, 2011.